National Institutes of Health (NIH) News This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Law enforcement seizures of psilocybin mushrooms rose dramatically between 2017-2022
NIH-supported research highlights need to better understand psilocybin in context of growing psychedelic use. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - February 6, 2024 Category: American Health Source Type: news

Comparing side effects after prostate cancer treatment
Men with cancer confined to the prostate experienced different long-term side effects depending on the type of treatment received. (Source: NIH Research Matters from the National Institutes of Health (NIH))
Source: NIH Research Matters from the National Institutes of Health (NIH) - February 6, 2024 Category: Consumer Health News Source Type: news

Preventing severe allergic reactions with nanoparticles
Researchers created nanoparticles that could deactivate immune cells and prevent severe allergic reactions in mice. (Source: NIH Research Matters from the National Institutes of Health (NIH))
Source: NIH Research Matters from the National Institutes of Health (NIH) - February 6, 2024 Category: Consumer Health News Source Type: news

Machine learning identifies federally protected waters
Researchers used machine learning to estimate which waters are protected by the Clean Water Act. (Source: NIH Research Matters from the National Institutes of Health (NIH))
Source: NIH Research Matters from the National Institutes of Health (NIH) - February 6, 2024 Category: Consumer Health News Source Type: news

New long-term data for Roche ’s Vabysmo show sustained retinal drying and vision improvements in retinal vein occlusion (RVO)
Vabysmo sustained robust drying of retinal fluid, often associated with distorted or blurry visionUp to 60% of people receiving Vabysmo were able to extend treatment intervals to three or four months apartDetailed results from two global Phase III RVO studies will be presented at Angiogenesis, Exudation, and Degeneration 2024Vabysmo is approved in the US for RVO, and in more than 90 countries around the world for people living with nAMD and DMEBasel, 1 February 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new 72-week data from two global Phase III studies, BALATON and COMINO, evaluating Vabysmo® (faricimab) i...
Source: Roche Investor Update - February 1, 2024 Category: Pharmaceuticals Source Type: news

New long-term data for Roche ’s Vabysmo show sustained retinal drying and vision improvements in retinal vein occlusion (RVO)
Vabysmo sustained robust drying of retinal fluid, often associated with distorted or blurry visionUp to 60% of people receiving Vabysmo were able to extend treatment intervals to three or four months apartDetailed results from two global Phase III RVO studies will be presented at Angiogenesis, Exudation, and Degeneration 2024Vabysmo is approved in the US for RVO, and in more than 90 countries around the world for people living with nAMD and DMEBasel, 1 February 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new 72-week data from two global Phase III studies, BALATON and COMINO, evaluating Vabysmo® (faricimab) i...
Source: Roche Media News - February 1, 2024 Category: Pharmaceuticals Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche exceeds guidance and achieves sales growth of 1% (CER) for 2023 despite sharp COVID-19 sales decline
Group salesgrow by 1%1 at constant exchange rates (CER; -7% in CHF), more than offsetting the decline in COVID-19-related sales and biosimilar erosion, and thereby exceeding 2023 guidanceExcluding COVID-19 products,Group sales increase by 8%Pharmaceuticals Divisionsalesincrease by 6% (excluding COVID-19 medicine Ronapreve: +9%) due to ongoing high demand for newer medicines, with eye medicine Vabysmo continuing to be the top growth driver, followed by Ocrevus (multiple sclerosis), Hemlibra (haemophilia A) and Polivy (blood cancer)Diagnostics Division salesare 13% lower due to high demand for COVID-19 tests in 2022; strong ...
Source: Roche Media News - February 1, 2024 Category: Pharmaceuticals Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche exceeds guidance and achieves sales growth of 1% (CER) for 2023 despite sharp COVID-19 sales decline
Group salesgrow by 1%1 at constant exchange rates (CER; -7% in CHF), more than offsetting the decline in COVID-19-related sales and biosimilar erosion, and thereby exceeding 2023 guidanceExcluding COVID-19 products,Group sales increase by 8%Pharmaceuticals Divisionsalesincrease by 6% (excluding COVID-19 medicine Ronapreve: +9%) due to ongoing high demand for newer medicines, with eye medicine Vabysmo continuing to be the top growth driver, followed by Ocrevus (multiple sclerosis), Hemlibra (haemophilia A) and Polivy (blood cancer)Diagnostics Division salesare 13% lower due to high demand for COVID-19 tests in 2022; strong ...
Source: Roche Investor Update - February 1, 2024 Category: Pharmaceuticals Source Type: news

NIH analysis reveals a significant rise in use of complementary health approaches, especially for pain management
Researchers examined the use of modalities such as yoga, meditation, massage over 20 years. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - January 31, 2024 Category: American Health Source Type: news

Abnormal proteins found in the spinal fluid of people with ALS and frontotemporal dementia
Proteins could serve as biomarkers that improve diagnosis and guide the development of novel therapies. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - January 31, 2024 Category: American Health Source Type: news

NIH study shows higher mortality rates for patients on respiratory support in rural intermediate care units
Findings highlight the importance of providing ICU-level care to rural patients with respiratory failure (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - January 31, 2024 Category: American Health Source Type: news

Viral protein fragments may unlock mystery behind serious COVID-19 outcomes
Key takeawaysThere remains no clear explanation for why COVID-19, caused by SARS-CoV-2, can result in severe outcomes or death while other coronaviruses just cause common colds, or why COVID-19 symptoms persist after the coronavirus that causes it has been eliminated.A UCLA-led research team has shown that fragments of the coronavirus may drive inflammation by mimicking the action of specific immune molecules in the body.The findings could contribute to not only the understanding and treatment of COVID-19 but also efforts to detect coronaviruses with the potential to cause pandemics before they become widespread.There are ...
Source: UCLA Newsroom: Health Sciences - January 31, 2024 Category: Universities & Medical Training Source Type: news

NIH panel to launch urgent investigation amid evidence Alzheimer's can SPREAD between people: Nearly 8,000 Americans received injection that can transmit memory-robbing condition
US scientists at the National Institutes of Health (NIH) are now preparing to 're-analyze' their data to detect a link to Alzheimer's in their patients. (Source: the Mail online | Health)
Source: the Mail online | Health - January 30, 2024 Category: Consumer Health News Source Type: news

Switching to vegan or ketogenic diet rapidly impacts immune system
NIH study finds distinct immune responses occur quickly when diets change, more research needed to determine health effects. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - January 30, 2024 Category: American Health Source Type: news

Will new CPT codes spark utilization of quantitative MRI?
Efforts to bring quantitative MRI analysis into clinical practice received a boost with the availability of two new Category III Current Procedural Terminology (CPT) codes for brain MRI. Effective January 1, 2024, the new codes, 0865T and 0866T, support the use of software to analyze brain MRI exams with comparison to prior studies. AI software would qualify under the Category III CPT codes, which are for new and emerging technology: 0865T -- qMRI analysis of the brain with comparison to prior MR study(ies), including lesion identification, characterization, and quantification, with brain volume(s) quantification and/o...
Source: AuntMinnie.com Headlines - January 30, 2024 Category: Radiology Authors: Liz Carey Tags: Artificial Intelligence SENL Source Type: news